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How do natural, thymus-derived T
regs
 
work? This question has preoccupied and 
perplexed T cell biologists for nearly two 
decades (Tang and Bluestone, 2008; Vignali 
et al., 2008; Workman et al., 2009). As with 
all important questions, there are some 
issues where there is a general consensus 
and others where there is still considerable 
disagreement. I would venture that most 
would agree with the following four basic 
tenets related to T
reg
 function.
First, T
regs
 are a critical peripheral toler-
ance mechanism that maintains immune 
homeostasis and prevents widespread 
autoimmunity (Ramsdell, 2003; Sakaguchi, 
2003; Fontenot and Rudensky, 2005). Thus, 
determining how T
regs
 work is a very impor-
tant goal.
Second, T
regs
 can suppress or modulate 
the function of a wide variety of cell popu-
lations, in diverse anatomical locations and 
in multiple disease situations (Tang and 
Bluestone, 2008).
Third, T
regs
 have an extensive arsenal and 
can utilize multiple contact-dependent and 
contact-independent mechanisms (Shevach 
et al., 2006; Vignali et al., 2008). This may be 
important because not all cell populations 
will be sensitive to all T
reg
 mechanisms.
Fourth, in addition to natural, thymus-
derived T
regs
, there are several induced T
reg
 
(iT
reg
) populations that can be generated in 
vitro or directly by T
regs
 via one of several 
inhibitory cytokines (TGFβ, IL-10, IL-35; 
Shevach, 2006; Collison and Vignali, 2008). 
The mechanism of suppression used by 
these populations seems less complicated 
with each appearing to depend on one key 
inhibitory cytokine. Thus our discussion 
here will focus on natural T
regs
.
However, I would argue that we know 
far less than we think we do about natural 
T
reg
 function and there is probably more 
contention than consensus. It is likely 
that continued, extensive analysis, and 
unique tools and approaches are likely to 
be required before a clear picture emerges. 
Some of these issues can be encapsulated 
around three key questions that pertain to 
T
reg
 function.
Which mechanisms are most important? 
This remains a contentious issue with each 
mechanism having its set of protagonists 
and antagonists. The mechanisms utilized by 
natural T
regs
 that have probably been exam-
ined and discussed the most are inhibitory 
cytokines (TGFβ, IL-10, IL-35), inhibitory 
receptors (CTLA4, LAG-3), cytotoxicity 
(Granzyme/Perforin) and metabolic dis-
ruption (IL-2 deprivation-mediated apop-
tosis, adenosine; Shevach et al., 2006; Tang 
and Bluestone, 2008; Vignali et al., 2008). 
Of course there may be several mechanisms 
that are important, with each contributing 
significantly in different disease scenarios, 
anatomical locations or against diverse cell 
types. Whether this is reality or appease-
ment remains to be resolved.
Before one determines if a mechanism is 
important, one would first need to obtain 
convincing in vivo evidence that a particular 
mechanism has a clearly definable physi-
ologic impact. In my view, too many strong 
conclusions have been derived from exclu-
sively or predominantly in vitro studies. 
Even when in vivo experiments have been 
performed, they are either limited to one 
model system or have potential, inherent 
weaknesses or caveats. It is hard to define 
what is “sufficient” but it seems reasonable 
to propose that data should be derived from 
multiple in vivo models (at least three) using 
(1) mice harboring conditionally (and ide-
ally temporally) deleted alleles and (2) in 
vivo blockade/neutralization with a specific 
monoclonal antibody. Indeed, one could 
argue that no proposed T
reg
 mechanism has 
been extensively assessed in vivo thus far. 
Although we have championed the poten-
tial importance of IL-35 using five in vivo 
model systems with neutralizing antibod-
ies and mutant T cell populations targeting 
the cytokine and its receptor (Collison et al., 
2007, 2010, 2012), I would be the first to 
admit that more remains to be determined 
regarding the physiological importance of 
IL-35. So for mechanisms that have not 
reached this bar, further analysis is clearly 
required. Of course a major challenge is 
that some of these mechanisms may uti-
lize molecules that also contribute to T
reg
 
development or homeostasis. Thus it may 
be very difficult, or even impossible, to 
divorce their roles in T
reg
 function versus 
development/homeostasis. Furthermore, 
some mechanisms may be hard to target 
without affecting other cellular processes.
The current debate regarding the impor-
tance of one proposed T
reg
 mechanism illus-
trates many of these issues. T
regs
 express high 
levels of the high affinity IL-2 receptor 
(CD25; Sakaguchi et al., 1995). It was ini-
tially proposed that T
regs
 may act as a “sink” 
absorbing IL-2 from the local environment, 
thereby depriving recently stimulated T 
cells from the IL-2 required to initiate 
proliferation and subsequent differentia-
tion. Subsequent analysis of mice lacking 
the capacity to make IL-2 or lacking CD25 
expression revealed that IL-2 plays a critical 
role in maintaining peripheral T
reg
 homeo-
stasis (D’Cruz and Klein, 2005; Fontenot 
et al., 2005). It was suggested that these 
data refuted the idea that T
regs
 act as an IL-2 
“sink,” although T
reg
 function in vivo was 
not directly examined (Maloy and Powrie, 
2005). More recently, it has been suggested 
that IL-2 deprivation-mediated apopto-
sis, facilitated by high CD25 expression, 
is a prominent mechanism of suppression 
used by T
regs
 (Pandiyan et al., 2007). These 
conclusions were supported predominantly 
by the observation that T cells targeted by 
T
regs
 die by apoptosis in in vitro assays but 
are resistant if they lack Bim, a pro-apo-
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deficient T
regs
 were fully functional in vitro 
and in vivo, essentially indistinguishable 
from wild type T
regs
 (Pillai et al., 2011). 
Thus, they seemed to have gained rather 
than lost function. Subsequent analysis 
revealed that the loss of IL-10 and IL-35 
was compensated for by the concurrent 
increase in cathepsin E (CTSE) expression. 
This appeared to be required to facilitate 
the expression and/or release of TRAIL, a 
member of the TNF superfamily that can 
mediate apoptosis, programmed necrosis 
(necroptosis) or suppress proliferation 
via its surface bound form or as a soluble 
trimer (Wang and el-Deiry, 2003; Schaefer 
et al., 2007). Importantly, this rendered 
IL-10/IL-35 double-deficient T
regs
 func-
tionally dependent on TRAIL in vitro and 
in vivo (Pillai et al., 2011). These data high-
light two important concepts. First, the loss 
of certain regulatory mechanisms may 
result in unforeseen molecular changes 
which facilitate functional compensation 
by the upregulation of another inhibitory 
mechanism. Second, this study revealed 
that unappreciated cross-regulatory path-
ways may exist which control the utiliza-
tion of certain suppressive mechanisms. 
Collectively this may serve to facilitate 
T
reg
 functional plasticity. Whether such 
mechanisms operate in vivo in the absence 
of genetic manipulation remains to be 
determined. However, it is possible that 
the mechanisms that are dominant differ 
in T
regs
 from different genetic backgrounds. 
Indeed, TRAIL is not a major mechanism 
used by C57BL/6 T
regs
, which express low 
levels of CTSE, but may be a more domi-
nant mechanism used by Balb/c T
regs
, which 
coincidentally express high levels of CTSE 
(Pillai et al., 2011). Additional studies will 
clearly be required to determine the prev-
alence of T
reg
 functional plasticity caused 
by divergent genetic backgrounds and/or 
altered environmental circumstances.
Is T
reg
 function altered in response to their 
environment? While this was addressed in 
part in the previous section, there are two 
other important points to make here. First, 
several recent and exciting studies have high-
lighted the importance of specific transcrip-
tion factors in shaping T
reg
 migration and 
function toward the control of particular 
Th responses (Chaudhry et al., 2009; Koch 
et al., 2009; Zheng et al., 2009). However, 
the precise molecular mechanism behind 
these observations remains obscure and an 
Regardless of which side of this debate 
your views lie, it is clear that further analy-
sis, especially using more sophisticated in 
vivo analysis and model systems, will be 
required to provide further insight into 
this controversy. While we do not claim 
that T
regs
 cannot mediate suppression by 
any cell death pathway under any circum-
stances, I would respectfully argue that there 
is not yet sufficient data to conclude that 
IL-2 deprivation-mediated apoptosis is a 
prominent mechanism of T
reg
-mediated 
suppression (Pandiyan et al., 2007). Given 
the inextricable link between the role of 
CD25 in controlling T
reg
 homeostasis and 
its possible role in mediating suppression 
via IL-2 deprivation-mediated apoptosis, 
definitive conclusions may be hard to reach.
Given these issues, the debate over the 
importance of other mechanisms is likely to 
conjure similar discussions. Nevertheless, 
we need to persevere dissecting what is 
clearly a very important issue. A final 
thought on this question (sobering or excit-
ing depending on your point of view). It 
remains possible that some key T
reg
 mecha-
nisms have yet to be identified. Indeed, we 
have yet to define the function of many of 
the genes that are upregulated in T
regs
, espe-
cially when derived from disease locations 
(Vignali et al., 2008).
How many mechanisms do T
regs
 need? If 
we accept that T
regs
 may utilize many mecha-
nisms to mediate suppression, especially at 
sites of substantial inflammation, it would 
seem important to determine how many are 
required to sustain credible T
reg
 function. T
reg
 
depletion or absence results in the develop-
ment of severe autoimmunity, but this is not 
matched by the disruption of any known 
mechanism (Fontenot and Rudensky, 2005; 
Vignali, 2008). This suggests that either 
key mechanisms have yet to be identified 
or multiple mechanisms work in concert 
to mediate T
reg
 function. I have discussed 
this topic in the past (Vignali, 2008), and 
the bottom line is that we do not know the 
minimum number of mechanisms required 
for T
reg
 function or how many can be lost 
before T
regs
 become fully dysfunctional.
We recently began to address this issue 
with surprising results. We assessed the 
suppressive capacity of IL-10/IL-35 dou-
ble-deficient T
regs
 anticipating that they 
would exhibit functional defects that were 
greater than their single knockout counter-
parts. Surprisingly, IL-10/IL-35  double-
ptotic Bcl-2 family member. Bim binds to 
Bcl-2 in response to stress signals, such as 
growth factor deprivation, thereby prim-
ing the mitochondrial pathway of apopto-
sis (Kuwana et al., 2005). Bim−/− T cells are 
resistant to apoptosis induced by cytokine 
or growth factor withdrawal, particularly 
IL-2 (Bouillet et al., 1999). Curiously, 
Pandiyan and colleagues also showed that 
T
regs
 do not affect early activation or pro-
liferation of effector T cells which is at 
odds with the importance of IL-2-induced 
STAT5 activation during these early stages 
(Rawlings et al., 2011).
The importance of this mechanism 
remains controversial as several studies 
have suggested that IL-2 depletion alone is 
not required for the suppression of human 
T cells (Tran et al., 2009; Vercoulen et al., 
2009). More recently, we have revisited this 
issue to ask if T
regs
 suppress via programmed 
cell death pathways (Szymczak-Workman 
et al., 2011). Contrary to the findings of 
Pandiyan and colleagues, we clearly showed 
that T
reg
-mediated suppression of Bim−/−, 
Bim−/−Puma−/−, and Bcl-2 transgenic T cells 
is comparable to controls using a variety 
of in vitro and in vivo assays (Szymczak-
Workman et al., 2011). Our use of Bim−/−
Puma−/− mice was particularly revealing 
as they have been shown to be completely 
resistant to cytokine withdrawal (You et al., 
2006; Cho et al., 2009), and yet could be 
readily suppressed by T
regs
.
Even though in vitro assays can be very 
informative, too often strong conclusions 
are drawn from data obtained primarily 
from such assays, as highlighted above. 
When T cells are stimulated in vitro, sub-
stantial T cell apoptosis can occur if IL-2 
becomes limiting, and so T cell death can 
be readily observed in vitro in the absence 
of T
regs
. The paradox here is that T
reg
 assays 
can be established where suppression is 
observed and either there is significant 
effector T cell death or almost no death, 
questioning whether the latter has anything 
to do with T
reg
 function. Although Pandiyan 
and colleagues suggested that Bim−/− T cells 
were resistant to T
reg
-mediated suppression 
in an inflammatory bowel disease (IBD) 
model (Pandiyan et al., 2007), we showed 
in two in vivo models that Bim−/− T cells 
could be effectively suppressed by T
regs
 and 
that Bim−/− T cells had a far greater propen-
sity to convert into iT
regs
 in vivo (Szymczak-
Workman et al., 2011; Wang et al., 2012).
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important priority for future research. Also, 
one wonders if other transcription factors 
play similar functions in facilitating T
reg
 con-
trol of diverse cell types and environments. 
Second, we have previously postulated that 
T
regs
 receive molecular cues from their tar-
get population and local environment that 
potentiates or boosts their regulatory capac-
ity (Vignali et al., 2008). Indeed, we have 
shown that T
reg
:T cell target interaction can 
substantially boost T
reg
-mediated suppres-
sion (Collison et al., 2009; Chaturvedi et al., 
2011). While the molecular mechanism of 
T
reg
 functional potentiation remains to be 
determined, it is particularly intriguing that 
the transcriptional landscape of “boosted” 
T
regs
 versus “activated” T
regs
 is very differ-
ent, suggesting that a lot remains to be 
discovered.
In closing, while we have made substan-
tial progress in our quest to determine how 
T
regs
 work, it seems that much still remains 
to be discovered and clarified.
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